FogPharma

Our CEO Mathai Mammen, M.D., Ph.D. will be speaking at the upcoming #BioCenturyGrandRounds as part of an illustrious panel of biopharma, regulatory and clinical experts entitled “Data for purpose: go big, go deep, or go long?” The panel will discuss how researchers are prioritizing data collection and application in the setting of real-world logistical constraints, and what the future of improved data collection looks like.      Data science is core to our #drugdiscovery and development work at Fog. We’re applying physics-based computational methods and artificial intelligence to aid in the invention of Helicons, a powerful peptide modality capable of “drugging” what has thus far has been completely intractable.  The larger biopharmaceutical ecosystem is starting to pay close attention to the multiple important problems encountered en route to a medicine that can be addressed by emerging technologies.    Learn more about Grand Rounds and explore the full agenda here: https://lnkd.in/gakuvuEn   #DataScience #Biotech 

We’d like to introduce the newest member of #TeamFogPharma: Amrith Bennet, our new Associate Vice President, Toxicology. Amrith’s 20+ years of experience in drug discovery and development will deepen the talent of our already-exceptional R&D group. In his role, Amrith will oversee the design and execution of nonclinical safety programs, supporting the development of safe and effective new medicines from discovery through to market authorization.  This new position for Fog will enable us to continue to grow our pipeline and leverage our Helicon technology, in oncology and beyond, to make extraordinary medicines. Welcome to the team, Amrith!  #Biotech #DrugDiscovery 

FogPharma CEO Mathai Mammen, M.D., Ph.D. spoke recently with MIT Sloan CDO about the powerful convergence of the parallel revolutions in the medical sciences and data science (AI), its significance for those aspiring to work in the biopharma industry, and its role in driving the next wave of therapeutic breakthroughs.     Our discovery engine has been custom-built to create a powerful drug modality that allows us to pursue medicines not currently possible anywhere else. We have assembled a top-tier team that relentlessly invents what we need and aims to create unique and effective medicines.       Read the full article here: https://bit.ly/46ZI3IT        #Biotech #MachineLearning #AI 

We’re excited to be partnering with ARTBIO to together create a new category of #radiopharmaceuticals. Recently ARTBIO CEO Emanuele Ostuni spoke with Mayo Clinic medical oncologist Oliver Sartor about the immense therapeutic promise of radiopharmaceuticals and of the Lead-212 manufacturing platform ARTBIO has built. Speaking about our companies’ collaboration, Emanuele highlighted how Helicons’ unique properties enable our co-created medicines to reach a vast range of previously unreachable targets: "Hitting those targets requires conformational specificity that can be had with very specific platforms, such as the one that FogPharma has, with whom we've partnered, to find ligands to targets that aren't classically druggable, as one would say.” Learn more about ARTBIO’s approach and see the full video on UroToday + GU OncToday: https://bit.ly/4ccIz7u #DrugDiscovery #Biotech

As the world cheered on athletes at #Paris2024, we channeled that same spirit of friendly competition at our 4th annual Summer Olympics last week! Featuring events such as pinning sidechains onto Helicons, a pipette tip shooting contest, and a radiopharmaceutical-inspired relay, our version of the summer games put our creativity and problem-solving to the test and produced lots of opportunities for camaraderie and laughter.     We look forward to the Summer Olympics each year as a time to come together and strengthen the bonds that unite us. And in that respect, #TeamFogPharma definitely took home the gold last week! 🏅    Check out some of the highlights below.   #TeamBuilding #CompanyOffsite 

The Biotech Week Boston Awards celebrate organizations driving innovation in the life sciences, and we have been named a 2024 finalist! We’re proud to be recognized in the Boston Highlight category among other local companies who have had a standout year.    And the past year certainly has been momentous for our team as we work toward extraordinary impact for patients: we brought the first-ever Helicon drug candidate to the clinic, expanded our senior management team with several leading biotech executives who will play a critical role in realizing our long-term vision, raised a $145M Series E round and forged a partnership that expands our portfolio into radiopharmaceuticals.    See you on September 23rd, when winners will be announced at Biotech Week Boston! https://bit.ly/3Wt722s      #biotech #oncology #radiopharmaceuticals #biotechweekboston   

We’re proud to welcome Teresa Jurgensen, J.D., as the newest addition to our senior management team as General Counsel. Teresa is a seasoned business partner and lawyer who has spent the last two decades working in the biotech and pharma industries. We’re looking forward to Teresa’s partnership in guiding our continued growth as a company and contributing her expertise to all of our current and future strategic initiatives. Welcome to the team, Teresa! #TeamFogPharma #biotechnology

Join us in welcoming the newest addition to the FogPharma leadership team: Alex Hird, Fog’s Vice President, Medicinal Chemistry Design. Alex brings to Fog nearly two decades of experience building and leading high-performing research teams in oncology drug discovery. His expertise targeting difficult-to-drug proteins will be an asset in our work to deploy Helicons against previously intractable targets, and his experience with leading-edge computational design tools will enhance our work to blend data science with biomedical science to discover exceptional new medicines. We’re thrilled to have you on #TeamFogPharma, Alex! #biotechnology #oncology #chemistry

On this #NationalInternDay, a round of applause please for #TeamFogPharma’s talented group of summer interns and co-ops: Janmejay Vyas, a graduate student at Northeastern University; Rachel Fay Uy, an undergraduate at Boston University; and Hana von der Linden and Lauren Sherman, both undergrads at Northeastern. Curiosity and growth are core to our work at Fog. Helping develop the next generation of biotech innovators is one of the ways we live out that commitment. We’re proud to partner in that effort with Northeastern University and Project Onramp to provide opportunities for promising young people to enter the field of life sciences.    Janmejay, Rachel, Hana and Lauren, thank you for all you do and for joining our effort to fundamentally change the treatment landscape for patients living with devastating diseases. #biotechnology #internship

This week, the Alldus podcast hosted Fog Chief Data Officer, Brandon Allgood, Ph.D., for a discussion on his career applying machine learning and large-scale computational methods to improve human health. The conversation highlighted Brandon’s industry leadership and expertise in this important discipline and how we’re combining biology and chemistry with data science advances to revolutionize the discovery and development of transformational medicines.    Our data science efforts are robust and growing at Fog, and we’re building the team to support that growth. We’re currently hiring for the following roles on Brandon’s team:     - Sr. Scientist, Machine Learning   - Principal Data Product Engineer  - Sr. Data Scientist, Cheminformatics    Learn more about these positions here: https://bit.ly/3VSwmAx     #TeamFogPharma #BiotechJobs #machinelearning #artificialintelligence #AI